Aligos Therapeutics, Inc.
ALGS
$9.32
-$0.45-4.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.17M | 3.27M | 3.95M | 6.00M | 7.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.17M | 3.27M | 3.95M | 6.00M | 7.97M |
| Cost of Revenue | 61.28M | 68.41M | 70.27M | 76.50M | 75.59M |
| Gross Profit | -58.11M | -65.14M | -66.33M | -70.50M | -67.62M |
| SG&A Expenses | 20.40M | 21.22M | 22.83M | 23.37M | 25.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.68M | 89.62M | 93.10M | 99.86M | 100.77M |
| Operating Income | -78.50M | -86.35M | -89.15M | -93.86M | -92.80M |
| Income Before Tax | -73.84M | -52.91M | -130.88M | -76.68M | -75.52M |
| Income Tax Expenses | 346.00K | 350.00K | 331.00K | 274.00K | 212.00K |
| Earnings from Continuing Operations | -74.18 | -53.26 | -131.21 | -76.95 | -75.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.18M | -53.26M | -131.21M | -76.95M | -75.74M |
| EBIT | -78.50M | -86.35M | -89.15M | -93.86M | -92.80M |
| EBITDA | -77.56M | -85.41M | -88.13M | -92.68M | -91.57M |
| EPS Basic | -12.56 | -10.21 | -20.92 | -13.35 | -20.64 |
| Normalized Basic EPS | -7.82 | -6.35 | -13.04 | -8.23 | -12.79 |
| EPS Diluted | -19.79 | -17.45 | -20.92 | -13.35 | -20.64 |
| Normalized Diluted EPS | -7.93 | -6.46 | -13.04 | -8.23 | -12.79 |
| Average Basic Shares Outstanding | 31.31M | 27.22M | 25.06M | 23.85M | 19.31M |
| Average Diluted Shares Outstanding | 31.62M | 27.53M | 25.07M | 23.85M | 19.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |